GRADE 3A FOLLICULAR LYMPHOMA
Clinical trials for GRADE 3A FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new GRADE 3A FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for GRADE 3A FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Gentler antibody treatment could tame Slow-Growing lymphoma
Disease control Recruiting nowThis phase II trial is testing a low dose of mosunetuzumab, an antibody that helps the immune system attack cancer cells, in 20 people with slow-growing B-cell lymphoma who have not had prior treatment. The goal is to see if this lower dose can shrink tumors while causing fewer s…
Matched conditions: GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 23, 2026 19:36 UTC
-
New drug combo aims to control lymphoma without chemo
Disease control Recruiting nowThis phase 2 trial is testing a combination of two drugs, acalabrutinib and obinutuzumab, in people with untreated follicular lymphoma or other slow-growing non-Hodgkin lymphomas. The goal is to see if this drug pair can shrink tumors and control the disease. About 49 participant…
Matched conditions: GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 23, 2026 12:09 UTC
-
New drug duo aims to outsmart Hard-to-Treat lymphoma
Disease control Recruiting nowThis phase 2 trial is testing whether combining two drugs, pirtobrutinib and mosunetuzumab, can better treat follicular lymphoma that has relapsed or is refractory. Pirtobrutinib blocks a protein that helps cancer cells grow, while mosunetuzumab helps the body's immune T cells at…
Matched conditions: GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC